Going Private Under Rule 13e-3: Special Committees and Minority Protection

Rule 13e-3 under the Securities Exchange Act governs going-private transactions — tender offers, mergers, asset sales or any transaction that causes a class of registered equity securities to be delisted, by an affiliate of the issuer: a controlling shareholder, director, officer or their affiliates. The rule's premise is that affiliate-initiated take-privates carry inherent conflicts, so it imposes a disclosure regime beyond ordinary merger disclosure: the Schedule 13E-3 must disclose the purposes of the transaction, the alternatives considered, and — the load-bearing item — whether the affiliate reasonably believes the transaction is fair or unfair to unaffiliated security holders, together with the fairness opinion's analyses in full. Delaware overlays the process layer: entire-fairness review, avoidable through the MFW architecture of an effective special committee and a majority-of-the-minority vote.

USA Post publishes information about deal regulation, not legal or investment advice.

Who is an affiliate, and which transactions are covered?

Affiliate status is functional: a person who directly or indirectly controls, is controlled by, or is under common control with the issuer — controllers, directors, officers, and entities they hold (like the sponsor fund in a take-private of a portfolio company; private equity sponsors repeatedly litigate the definition, and the SEC staff has taken broad views of fund-family affiliates). Covered transactions include cash-out mergers, tender offers by affiliates, self-tenders, roll-ups, and the termination-of-reporting variants. The trigger is delisting — even a transaction leaving some public holders requires 13E-3 where the class comes off the exchange. Non-affiliate buyers taking a company private do not file 13E-3; their deal is ordinary M&A disclosure.

What must the Schedule 13E-3 disclose?

Beyond the merger proxy or tender offer documents, the 13E-3 adds: the transaction's purposes (stated specifically — why the affiliate is buying, including any inability to raise capital publicly or desire to realize value); the alternatives considered and the reasons each was rejected (continuing the public company, dividend recapitalization, sale to third parties); the factors behind the fairness determination, negative and positive, and a statement whether the affiliate believes the transaction is fair or unfair to the minority — with an "unfair" belief theoretically possible but never seen in practice; and the fairness opinion's underlying analyses, disclosed in enough detail that a holder can evaluate the DCF assumptions, multiples and premiums. Filing group members — every affiliate participating — must be identified. The 1995-2025 enforcement record shows the SEC's recurring targets: fairness opinions from conflicted bankers, purposes sections drafted as boilerplate, and undisclosed side arrangements among affiliates.

How does Delaware entire fairness layer in?

As the litigation shadow over the disclosure. A controller squeeze-out faces entire fairness unless MFW-qualified — special committee formed before negotiations with true bargaining power, plus an informed, non-waivable majority-of-the-minority vote. Management buyouts without a controlling shareholder face entire-fairness-style scrutiny through the Oculink-frame where management stands on both sides; the special committee is the standard mitigation. The two regimes interlock: the 13E-3 disclosure of the special committee's process — sessions held, advisors retained, price improvements won — is simultaneously the Delaware fair-dealing record. Defense counsel draft the 13E-3 with the Chancery complaint in mind, because the purposes-and-alternatives section is where plaintiffs' counsel mine for omissions: every alternative not disclosed becomes an unexplored option in litigation.

What are the recurring 13E-3 litigation patterns?

Three. Disclosure challenges: suits alleging the purposes, alternatives or fairness detail was incomplete — most settle with supplemental disclosures and mootness fees, but the Delaware docket's 2022-2025 tightening (rejecting trivial supplemental disclosures as mootness grounds) raised the pleading bar. Fairness trials: where MFW protections were absent or defective, post-closing entire-fairness litigation with damages measured against trial-date fair value. And SEC enforcement: conflicted-adviser fairness opinions (the recurring defect — bankers with fee interests tied to closing) drawing proceedings under the rule's antifraud companion, Section 13(e). The synthesis for deal-doers: the 13E-3's disclosure menu and Delaware's process menu answer the same question — was the minority genuinely protected — and each document should be drafted to support the other.

How should a take-private be structured compliantly?

1. Confirm affiliate status of every participant in the buying group — fund-family and management roll-over structures included.
2. Condition the transaction from the start on an effective special committee with authority to say no, formed before economic terms are discussed.
3. Give the committee genuinely independent advisers; scrutinize the banker's fee structure for closure-dependence.
4. Negotiate a non-waivable majority-of-the-minority condition with the vote taken on full disclosure.
5. Draft the 13E-3 purposes and alternatives sections as a candid narrative — the honest version is both the compliant one and the litigation-defense one.

Is going-private activity rising?

Cyclically, with 2024-2025 showing elevated take-private volume as public-market small caps carried compliance costs their valuations no longer justified, and sponsor-led deals dominated the larger end. For the public markets' smaller companies, the 13E-3 path — with its minority-protection architecture — is the standard exit; for investors, the 13E-3's disclosure sections are the diligence kit for judging any take-private: who believes it fair, why, what alternatives existed, and what the committee actually won.